Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Abstract Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, and iron chelators, have failed in disease-modification clini...
Main Authors: | Martin T. Henrich, Wolfgang H. Oertel, D. James Surmeier, Fanni F. Geibl |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Molecular Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13024-023-00676-7 |
Similar Items
-
Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
by: Pierpaolo Risiglione, et al.
Published: (2021-05-01) -
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
by: Seung Pil Yun, et al.
Published: (2018-01-01) -
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
by: Fanni F. Geibl, et al.
Published: (2024-10-01) -
Significance of Mitochondrial Dysfunction in the Pathogenesis of Parkinson's Disease
by: Alexander Blagov, et al.
Published: (2024-01-01) -
Mitochondrial Respiratory Chain Dysfunction—A Hallmark Pathology of Idiopathic Parkinson’s Disease?
by: Irene H. Flønes, et al.
Published: (2022-04-01)